Shares of Aptinyx Inc (NASDAQ:APTX) have been given an average rating of “Buy” by the six brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $15.00.

Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Aptinyx from a “buy” rating to a “hold” rating in a report on Monday, May 20th. Cantor Fitzgerald cut their price objective on Aptinyx from $18.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, March 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Aptinyx in a report on Friday, March 22nd.

In other news, Director Henry O. Gosebruch acquired 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $386,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.47% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New Leaf Venture Partners L.L.C. grew its stake in Aptinyx by 7.4% during the 1st quarter. New Leaf Venture Partners L.L.C. now owns 3,533,424 shares of the company’s stock worth $14,310,000 after purchasing an additional 243,345 shares in the last quarter. Partner Fund Management L.P. grew its stake in Aptinyx by 5.6% during the 4th quarter. Partner Fund Management L.P. now owns 1,852,132 shares of the company’s stock worth $30,634,000 after purchasing an additional 97,453 shares in the last quarter. BlackRock Inc. grew its stake in Aptinyx by 50.2% during the 4th quarter. BlackRock Inc. now owns 1,155,090 shares of the company’s stock worth $19,105,000 after purchasing an additional 386,018 shares in the last quarter. Morgan Stanley grew its stake in Aptinyx by 2,291.8% during the 1st quarter. Morgan Stanley now owns 512,560 shares of the company’s stock worth $2,076,000 after purchasing an additional 491,130 shares in the last quarter. Finally, Vanguard Group Inc grew its stake in Aptinyx by 371.0% during the 3rd quarter. Vanguard Group Inc now owns 296,717 shares of the company’s stock worth $8,593,000 after purchasing an additional 233,717 shares in the last quarter. 59.10% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:APTX traded up $0.04 on Friday, reaching $3.10. The company’s stock had a trading volume of 167,550 shares, compared to its average volume of 179,896. Aptinyx has a 12-month low of $2.97 and a 12-month high of $32.25. The company has a market capitalization of $102.70 million and a P/E ratio of -1.17.

Aptinyx (NASDAQ:APTX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04). The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $1.00 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%. Equities analysts expect that Aptinyx will post -2.25 EPS for the current year.

About Aptinyx

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.

See Also: What is a dead cat bounce?

Analyst Recommendations for Aptinyx (NASDAQ:APTX)

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.